image credit: Pexels

FDA sets date for Sarclisa in first-line multiple myeloma

May 28, 2024


The French pharma group has filed anti-CD38 antibody Sarclisa (isatuximab) for use in combination with Takeda’s Velcade (bortezomib), lenalidomide, and dexamethasone – known as the VRd regimen – in previously untreated multiple myeloma patients who are not eligible for or opt out of a bone marrow transplant.

The application is one of two that Sanofi hopes will unlock growth for Sarclisa, which has been approved for relapsed/refractory multiple myeloma alongside commonly used combination regimens since 2020.

Read More on Pharmaphorum